Brought to you by 
Celgene pays $1.1bn up front to buy Impact; $5.9bn in earn-outs possible
Jan 2018
Executive Summary
Celgene Corp. is paying $1.1bn up front, plus massive potential earn-outs, to acquire privately held cancer drug developer Impact Biomedicines.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Includes Earnout
- Intra-Biotech Deal
- Acquisition of Private Biotech
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene pays $1.1bn up front to buy Impact; $5.9bn in earn-outs possible
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice